TScan Therapeutics approves retention program with cash and RSUs for CEO and Chief Legal Officer

TScan Therapeutics, Inc.

CEO Gavin MacBeath receives $822,000 cash award and 2,400,000 RSUs under Retention Program.
CLSO Zoran Zdraveski receives $416,000 cash award and 1,050,000 RSUs under Retention Program.
Cash awards: first half paid Nov 2026 and Feb 2027; second half on in vivo solid tumor clinical milestone.
RSUs: one-third vest on financing milestone; remaining two-thirds over first two anniversaries of that milestone.
Program aims to retain key employees supporting company, granted under 2021 Equity Incentive Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.